Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy)

Strahlentherapie und Onkologie

Volumn 182, Issue 9, 2006, Pages 537-542

  Goldner, Gregor ^a   Wachter, Stefan ^b   Wachter Gerstner, Natascha ^b   Dieckmann, Karin ^b   Pötter, Richard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b University Hospital of Vienna ^*

Author keywords

bNED; Conformal radiotherapy; Long term results; Prostate cancer; Survival

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROSTATE CANCER; RADIATION DOSE; UROGENITAL TRACT DISEASE;

AGE FACTORS; AGED; AGED, 80 AND OVER; DATA INTERPRETATION, STATISTICAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33748137812     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1607-8     Document Type: Article

References (32)

1. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
2. Cavey ML, Bayouth JE, Colman M, et al. IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol 2005;181:431-41.
3. Critz FA, Williams WH, Holladay CT, et al. Post-treatment PSA < or = 0.2 ng/ mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 1999;54:968-71.
4. Crook J, Malone S, Perry G, et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000;48:355-67.
5. Dobler B, Mai S, Ross C, et al. Evaluation of possible prostate displacement induced by pressure applied during transabdominal ultrasound image acquisition. Strahlenther Onkol 2006;182:240-6.
6. De Meerleer G, Vakaet L, De Gersem W, et al. Direct segment aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer. Strahlenther Onkol 2004;180:136-43.
7. Gershkevitsh E, Clark CH, Staffurth J, et al. Dose to bone marrow using IMRT techniques in prostate cancer patients. Strahlenther Onkol 2005;181:172-8.
8. Gerstner N, Wachter S, Dorner D, et al. Significance of a rectal balloon as internal immobilization device in conformal radiotherapy of prostatic carcinoma. Strahlenther Onkol 1999;175:232-8.
9. Grosu AL, Piert M, Weber WA, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005;181:483-99.
10. Hanks GE, Hanlon AL, Epstein B, et al. Dose response in prostate cancer with 8-12 years follow-up. Int J Radiat Oncol Biol Phys 2002;54:427-35.
11. Hanks GE, Lee WR, Hanlon AL, et al. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 ng/ml. Int J Radiat Oncol Biol Phys 1996;35:861-8.
12. Koelbl O, Schwab F, Bratengeier K, et al. Radiotherapy of prostate cancer with multileaf collimators (MLCs) optimization of the undulating dose distribution at the MLC edge. Strahlenther Onkol 2005;181:108-12.
13. Mayer R, Pummer K, Quehenberger F, et al. Analysis of competing risk parameters in irradiated prostate cancer patients. Strahlenther Onkol 2003;179:452-7.
14. Mock U, Bogner J, Georg D, et al. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy. Strahlenther Onkol 2005;181:448-55.
15. Perez CA, Michalski JM, Lockett MA. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint. Int J Radiat Oncol Biol Phys 2001;49:1287-96.
16. Pilepich MV, Winter K, Lawton CA, et al. Androgen supression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90.
17. Pollack A, Hanlon A, Horwitz EM, et al. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol 2003;21:200-8.
18. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol 2004;171:1132-6.
19. Pollack A, Zagars GK, Antolak JA, et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2002;54:677-85.
20. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18:3904-11.
21. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
22. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, Level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2002;54:1036-46.
23. Schulte RW, Slater JD, Rossi CJ, et al. Value and perspectives of proton radiation therapy for limited stage prostate cancer. Strahlenther Onkol 2000;176:3-8.
24. Statistik Austria. Sterbetafel 2000/2002 für Österreich (www.statistik.at/fachbereich_03/Stt2000_2002.xls).
25. Teh BS, Mai WY, Grant WH 3rd, et al. Intensity-modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances tumor control. Cancer Invest 2002;20:437-51.
26. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:553-61.
27. Vicini FA, Kestin LL, Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 2000;88:2305-18.
28. Wachter S, Gerstner N, Goldner G, et al. Three-dimensional conformal photon radiotherapy at a moderate dose level of 66 Gy for prostate carcinoma: early results. Strahlenther Onkol 1999;175:84-6.
29. Wachter-Gerstner N, Wachter S, Goldner G, et al. Biochemical response after 3-D conformal radiotherapy of localized prostate cancer to a total dose of 66 Gy. 4-year results. Strahlenther Onkol 2002;178:542-7.
30. Wiegel T, Tepel J, Schmidt R, et al. Long-term results of patients with clinical stage C prostate cancer treated by phototherapy and early orchiectomy. A retrospective analysis of 169 cases. Strahlenther Onkol 1996;172:596-603.
31. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
32. Zelefsky MJ, Moughan J, Owen J, et al. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:1053-61.